HUTCHMED (CHINA) LIMITED - Form 6-K Summary (Nov 2025)

This Form 6-K filing indicates the release of material business updates via Exhibit 99.1.

• Key Event: Release of a press release detailing pipeline and business progress presented at the recent R&D Updates Event.

Investors should review Exhibit 99.1 for specifics on drug pipeline advancements, strategic initiatives, and any operational milestones reported during the event.

• Filing Date: November 3, 2025

• CFO Signature: Johnny Cheng

  HUTCHMED R&D Update (Nov 2025)

  HUTCHMED unveiled its next-gen __ATTC p